South Korea orders Boryung to divest cancer-drug business to clear Sanofi deal
South Korean pharmaceutical company Boryung has been ordered to divest its cancer-drug business as a condition of approval for its acquisition of the global commercial rights to Sanofi's chemotherapy treatment Taxotere,...To view the full article, register now.
Already a subscriber? Click here to view full article